Karyopharm Therapeutics, Inc. (KPTI)
0.8022
-0.06
(-7.45%)
USD |
NASDAQ |
Oct 02, 16:00
0.8487
+0.05
(+5.80%)
After-Hours: 20:00
Karyopharm Therapeutics Enterprise Value : 209.28M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 209.28M |
| October 01, 2026 | 210.75M |
| September 30, 2026 | 218.76M |
| September 29, 2026 | 218.42M |
| September 28, 2026 | 227.83M |
| September 25, 2026 | 227.83M |
| September 24, 2026 | 230.32M |
| September 23, 2026 | 230.78M |
| September 22, 2026 | 232.37M |
| September 21, 2026 | 233.27M |
| September 18, 2026 | 233.73M |
| September 17, 2026 | 231.68M |
| September 16, 2026 | 229.64M |
| September 15, 2026 | 226.01M |
| September 14, 2026 | 227.38M |
| September 11, 2026 | 227.60M |
| September 10, 2026 | 227.83M |
| September 09, 2026 | 229.42M |
| September 08, 2026 | 230.10M |
| September 04, 2026 | 231.68M |
| September 03, 2026 | 231.23M |
| September 02, 2026 | 231.68M |
| September 01, 2026 | 233.05M |
| August 31, 2026 | 237.81M |
| August 28, 2026 | 233.50M |
| Date | Value |
|---|---|
| August 27, 2026 | 235.09M |
| August 26, 2026 | 235.54M |
| August 25, 2026 | 234.63M |
| August 24, 2026 | 233.27M |
| August 21, 2026 | 235.54M |
| August 20, 2026 | 232.37M |
| August 19, 2026 | 236.45M |
| August 18, 2026 | 234.86M |
| August 17, 2026 | 232.14M |
| August 14, 2026 | 236.90M |
| August 13, 2026 | 236.22M |
| August 12, 2026 | 237.13M |
| August 11, 2026 | 238.72M |
| August 10, 2026 | 235.54M |
| August 07, 2026 | 239.17M |
| August 06, 2026 | 235.31M |
| August 05, 2026 | 234.41M |
| August 04, 2026 | 235.54M |
| August 03, 2026 | 235.77M |
| July 31, 2026 | 234.63M |
| July 30, 2026 | 350.08M |
| July 29, 2026 | 346.67M |
| July 28, 2026 | 351.89M |
| July 27, 2026 | 351.89M |
| July 24, 2026 | 359.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals, Inc. | 11.04B |
| Relay Therapeutics, Inc. | 3.263B |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -67.02M |
| Revenue (Quarterly) | 33.43M |
| Total Expenses (Quarterly) | 100.46M |
| EPS Diluted (Quarterly) | -2.316 |
| Gross Profit Margin (Quarterly) | 96.75% |
| Profit Margin (Quarterly) | -200.5% |
| Earnings Yield | -1.63K% |
| Normalized Earnings Yield | -1326.76 |